Ren Bo, Feng Que, He Shan, Li Yanfeng, Fan Jiadong, Chai Guangquan, Liu Le, Liu Haiyun, Yang Chunhao, Wang Yingdi, Liu Huihui, Liu Huanyue, Song Yafan
Department of Stomatology, the Fourth Medical Center, Chinese PLA General Hospital, No. 51 Fucheng Road, Beijing, 100048, Haidian District, China.
J Inflamm (Lond). 2021 May 22;18(1):18. doi: 10.1186/s12950-021-00281-9.
Anti-vascular endothelial growth factor (VEGF) has been used as a therapeutic drug for the treatment of some human diseases. However, no systematic evidence is performed for assessing the role of VEGF in periodontitis. We carried out a comprehensive analysis to explore the role of VEGF in patients with periodontitis.
Multiple databases were searched for eligible studies. The pooled standardized mean difference (SMD) and odds ratio (OR) with the corresponding 95% confidence interval (CI) were applied to evaluate the effect sizes. Clinical data validation from microarray analysis was used. Pathway and process enrichment analysis were also investigated.
Finally, 16 studies were included in this analysis. Overall, there was a significantly higher level of VEGF expression in periodontitis than in healthy control groups (OR = 16.64, 95% CI = 6.01-46.06, P < 0.001; SMD = 2.25, 95% CI = 1.25-3.24, P < 0.001). Subgroup analysis of ethnicity showed that VEGF expression was still correlated with periodontitis in the Asian and European populations. No correlation was observed between VEGF expression and age, gender, and pathological type. A large clinical sample data (427 periodontitis patients and 136 healthy controls) further validated that VEGF expression was higher in periodontitis than in healthy control groups (P = 0.023). VEGF was involved in many functions such as blood vessel development, response to growth factor, cell proliferation, and cell adhesion.
High levels of VEGF were credible implications for the development of periodontitis. Anti-VEGF therapy may be valuable for the treatment of periodontitis in clinical management.
抗血管内皮生长因子（VEGF）已被用作治疗某些人类疾病的药物。然而，目前尚无系统的证据来评估VEGF在牙周炎中的作用。我们进行了一项综合分析，以探讨VEGF在牙周炎患者中的作用。
检索多个数据库以获取符合条件的研究。采用合并的标准化均数差（SMD）和比值比（OR）以及相应的95%置信区间（CI）来评估效应大小。使用来自微阵列分析的临床数据验证。还进行了通路和过程富集分析。
最终，本分析纳入了16项研究。总体而言，牙周炎患者中VEGF表达水平显著高于健康对照组（OR = 16.64，95%CI = 6.01 - 46.06，P < 0.001；SMD = 2.25，95%CI = 1.25 - 3.24，P < 0.001）。种族亚组分析表明，在亚洲和欧洲人群中，VEGF表达仍与牙周炎相关。未观察到VEGF表达与年龄、性别和病理类型之间存在相关性。一项大型临床样本数据（427例牙周炎患者和136例健康对照）进一步验证了牙周炎患者中VEGF表达高于健康对照组（P = 0.023）。VEGF参与了许多功能，如血管发育、对生长因子的反应、细胞增殖和细胞黏附。
VEGF水平升高是牙周炎发生的可靠指标。抗VEGF治疗在临床管理中可能对牙周炎的治疗具有重要价值。
